PMID- 25906114
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20181113
IS  - 2211-3436 (Electronic)
IS  - 2211-3428 (Print)
IS  - 2211-3428 (Linking)
VI  - 38
IP  - 3
DP  - 2015 Jun
TI  - Chromosome 17 copy number changes in male breast cancer.
PG  - 237-45
LID - 10.1007/s13402-015-0227-7 [doi]
AB  - BACKGROUND: Overall, HER2-amplified female breast cancer (FBC) is associated with 
      a high grade, an aggressive phenotype and a poor prognosis. In male breast cancer 
      (MBC) amplification of HER2, located on chromosome 17, occurs at a lower 
      frequency than in FBC, where it is part of complex rearrangements. So far, only 
      few studies have addressed the occurrence of chromosome 17 alterations in small 
      MBC cohorts. METHODS: Multiplex ligation-dependent probe amplification (MLPA) and 
      fluorescence in situ hybridization (FISH) were used to detect and characterize 
      copy number changes on chromosome 17 in a cohort of 139 MBC. The results obtained 
      were compared to those in FBC, and were correlated with clinicopathological 
      features and patient outcome data. RESULTS: We observed a lower frequency of 
      chromosome 17 copy number changes with less complex rearrangement patterns in MBC 
      compared to FBC. Chromosome 17 changes in MBC included gains of 17q and losses of 
      17p. Whole chromosome 17 polyploidies were not encountered. Two recurrent 
      chromosome 17 amplicons were detected: on 17q12 (encompassing the NEUROD2, HER2, 
      GRB7 and IKZF3 gens) and on 17q23.1 (encompassing the MIR21 and RPS6KB1 genes). 
      Whole arm copy number gains of 17q were associated with decreased 5 year survival 
      rates (p = 0.010). Amplification of HER2 was associated with a high tumor grade, 
      but did not predict patient survival. Although copy number gains of HER2 and 
      NEUROD2 were associated with a high tumor grade, a high mitotic count and a 
      decreased 5 year survival rate (p = 0.015), only tumor size and NEUROD2 copy 
      number gains emerged as independent prognostic factors. CONCLUSIONS: In MBC 
      chromosome 17 shows less complex rearrangements and fewer copy number changes 
      compared to FBC. Frequent gains of 17q, encompassing two distinct amplicons, and 
      losses of 17p were observed, but no whole chromosome 17 polyploidies. Only 
      NEUROD2 gains seem to have an independent prognostic impact. These results 
      suggest different roles of chromosome 17 aberrations in male versus female breast 
      carcinogenesis.
FAU - Lacle, Miangela M
AU  - Lacle MM
AD  - Department of Pathology, University Medical Center Utrecht, PO Box 85500, 3508 
      GA, Utrecht, The Netherlands.
FAU - Moelans, Cathy B
AU  - Moelans CB
FAU - Kornegoor, Robert
AU  - Kornegoor R
FAU - van der Pol, Carmen
AU  - van der Pol C
FAU - Witkamp, Arjen J
AU  - Witkamp AJ
FAU - van der Wall, Elsken
AU  - van der Wall E
FAU - Rueschoff, Josef
AU  - Rueschoff J
FAU - Buerger, Horst
AU  - Buerger H
FAU - van Diest, Paul J
AU  - van Diest PJ
LA  - eng
PT  - Journal Article
DEP - 20150424
PL  - Netherlands
TA  - Cell Oncol (Dordr)
JT  - Cellular oncology (Dordrecht)
JID - 101552938
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/genetics
MH  - Breast Neoplasms, Male/*genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Female
MH  - *Gene Dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiplex Polymerase Chain Reaction
PMC - PMC4445249
EDAT- 2015/04/24 06:00
MHDA- 2016/03/24 06:00
PMCR- 2015/04/24
CRDT- 2015/04/24 06:00
PHST- 2015/04/01 00:00 [accepted]
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
PHST- 2015/04/24 00:00 [pmc-release]
AID - 227 [pii]
AID - 10.1007/s13402-015-0227-7 [doi]
PST - ppublish
SO  - Cell Oncol (Dordr). 2015 Jun;38(3):237-45. doi: 10.1007/s13402-015-0227-7. Epub 
      2015 Apr 24.